TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00769028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperimmune caprine serum
Description: Subcutaneous injection of serum, 1ml twice weekly for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albumin
Description: Subcutaneous injection of albumin, 1ml twice weekly for 6 months
Study: NCT00975065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin 50 mg bid plus metformin 1500mg (Galvus+Diabex)
Description: vildagliptin 50 mg bid plus metformin 1500mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin 1500mg plus metformin 500mg or 1000mg (Diabex)
Description: metformin 1500mg plus metformin 500mg or 1000mg
Study: NCT02634021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine group
Description: intravenous loading of dexmedetomidine for 1 mcg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam group
Description: intravenous loading of midazolam for 0.1 mg/kg
Study: NCT00582738

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CsA-TAC (standard Treatment)
Description: Continuation of current immunosuppressive regimen (continuation of CNI with or without MPA, with or without steroids) / no everolimus introduction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Hepatitis C recurrence after orthotopic liver transplantation (OLT)
Study: NCT02538133

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 99mTc-Exametazime (HMPAO)-labeled leukocytes
Description: Hybrid tomoscintigraphy with labeled leucocytes for patients with suspected vascular prosthesis infection
Study: NCT02300597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet based support and coaching
Description: Young people between age 15 and 25 with ADHD and/or autism spectrum disorders are offered internet-based support and coaching during eight weeks (chat and e-mail). Data is collected before and after the intervention and six months after end of treatment using self-report questionnaires pertaining to sense of coherence, self-esteem, quality of life, depressive and anxiety symptoms and socioeconomic status. Parents complete an assessment scale for the next of kin. After treatment the young people are interviewed regarding the quality of the intervention.
Study: NCT00652899

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: All patients are to receive allopurinol 300 mg PO daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post natural killer cell infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: All patients are to receive allopurinol 300 mg PO daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post natural killer cell infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/m\^2 on Days 4 and 5 preceding natural killer cell infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/m\^2 on Days 4 and 5 preceding natural killer cell infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: 25 mg/m\^2 on Days 6 through 2 preceding natural killer cell infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: 25 mg/m\^2 on Days 6 through 2 preceding natural killer cell infusion.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: 200 cGy Day 1 preceding natural killer cell infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic natural killer cells
Description: Given day 0 - dose of 1.5-8.0 \* 10\^7/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic natural killer cells
Description: Given day 0 - dose of 1.5-8.0 \* 10\^7/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: 10 MU 3 times/week for a total of 6 doses beginning Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: 10 MU 3 times/week for a total of 6 doses beginning Day 0
Study: NCT02706028

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: underwater ultrasound
Description: underwater US therapy with an intensity of 0.7 W/cm2 in a total of 10 sessions (10 working days) using a 830 kHz ULTRON home OE-302® device with treatment head size of 4.2 cm2.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham underwater ultrasound
Description: ULTRON home OE-302® device is not turned on
Study: NCT04478032

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: deep transcranial magnetic stimulation with H7 coil
Description: low frequency(1Hz) deep transcranial magnetic stimulation on ACC .Duration:20 days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: deep transcranial magnetic stimulation with H7 coil
Description: low frequency(1Hz) deep transcranial magnetic stimulation on ACC .Duration:20 days.
Study: NCT02675413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl Fumarate
Description: Open-label
Study: NCT00605670

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: patients will fill out two questionnaires post surgery

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: Patient will fill out questionnaire before and 3 to 6 months after treatment.
Study: NCT03443284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Partner
Description: Health Partner is a combination of an iPhone or iPod Touch Operating System mobile application and a health care provider portal.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Care
Description: Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Providence Health \& Services.
Study: NCT03984604

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHI-921
Description: a standardized cannabis extract in sunflower oil administered in oral liquid (oil) form

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a vehicle oil will match CHI-921
Study: NCT03642223

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stable iron isotopes
Description: Participants have to consume a test meal containing stable iron isotopes in order to determine iron absorption

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stable iron isotopes
Description: Participants have to consume a test meal containing stable iron isotopes in order to determine iron absorption

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stable iron isotopes
Description: Participants have to consume a test meal containing stable iron isotopes in order to determine iron absorption
Study: NCT03605303

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test/Control
Description: Subjects that are between the ages of 18-70 years old and habitual wearers of hydrogel daily disposable contact lenses will be randomly assigned to Test/Control sequence with a 7 to 9-day washout period in between treatments

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test/Control
Description: Subjects that are between the ages of 18-70 years old and habitual wearers of hydrogel daily disposable contact lenses will be randomly assigned to Test/Control sequence with a 7 to 9-day washout period in between treatments

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control/Test
Description: Subjects that are between the ages of 18-70 years old and habitual wearers of hydrogel daily disposable contact lenses will be randomly assigned to Control/Test sequence with a 7 to 9-day washout period in between treatments

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control/Test
Description: Subjects that are between the ages of 18-70 years old and habitual wearers of hydrogel daily disposable contact lenses will be randomly assigned to Control/Test sequence with a 7 to 9-day washout period in between treatments
Study: NCT01973907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid Sparing Resuscitation Strategy
Description: Tier 1: Initiate IV/IO vasoactive medication infusion support immediately. Further IV/IO isotonic fluid bolus therapy \[crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)\] should be avoided; small volume isotonic fluid boluses \[5-10 mL/kg (250-500 mL for participants ≥ 50 kg)\] may be provided if required due to A. Clinically unacceptable delay in ability to initiate vasoactive medication infusion(s) and/or 2. Documented intravascular hypovolemia.~Tier 2: Vasoactive medication(s) should be preferentially titrated/escalated to achieve recommended ACCM hemodynamic goals. Further IV/IO isotonic fluid bolus therapy \[crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)\] should be avoided; small volume isotonic fluid boluses \[5-10 mL/kg (250-500 mL for participants ≥ 50 kg)\] may be provided if required due to A. Documented intravascular hypovolemia.~Intervention end: Patient is free from vasoactive medication support and shock is reversed.
Study: NCT01167907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Description: 0.2% ropivacaine by elastomeric infusion pump at 5ml/h started within 6h of catheter placement

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saline
Description: saline (control) by elastomeric infusion pump at 5ml/h started within 6h of catheter placement

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline (control) by elastomeric infusion pump at 5ml/h started within 6h of catheter placement
Study: NCT02749383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 cream 0.3%
Description: Topical application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 cream 1.0%
Description: Topical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PAC-14028 cream vehicle
Description: Topical application
Study: NCT00468936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myfortic
Description: enteric coated Cellcept pills in applicable dose for patient
Study: NCT00259298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriparatide
Description: Subcutaneous, 20 microgram (mcg)/day, 18 months
Study: NCT00180297

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotak Reliance G
Description: Reliance G is a defibrillation lead to be placed in the right ventricle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotak Reliance G
Description: Reliance G is a defibrillation lead to be placed in the right ventricle.
Study: NCT05385445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback
Description: The investigators conducted a clustered randomized trial of primary care providers in Manitoba, Canada participating in the Manitoba Primary Care Research Network (MaPCReN) to assess the impact of Audit \& Feedback interventions to change prescribing and laboratory ordering.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback
Description: The investigators conducted a clustered randomized trial of primary care providers in Manitoba, Canada participating in the Manitoba Primary Care Research Network (MaPCReN) to assess the impact of Audit \& Feedback interventions to change prescribing and laboratory ordering.
Study: NCT01721642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apica Cardiovascular ASC Access, Stability and Closure Device
Description: Access, stabilisation and closure of trans-apical approach for TAVI
Study: NCT01643811

Intervention type: PROCEDURE
Intervention: gastrectomy
Description: subtotal gastrectomy with gastroduodenostomy or loop gastrojejunostomy or Roux Y gastrojejunostomy total gastrectomy with Roux Y esophagojejunostomy

Intervention type: PROCEDURE
Intervention: Endoscopic submucosal dissection
Description: endoscopic submucosal dissection
Study: NCT00309842

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: All patients will receive G-CSF 5 mcg/kg/day intravenously(IV) (dose rounded to vial size) based on the actual body weight IV beginning on day +1 after umbilical cord blood (UCB) infusion. G-CSF will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10\^9/L for three consecutive days.
Study: NCT01400243

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Nicotine patch 7mg
Study: NCT00309842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide to be administered with high volume fluid flush and mesna (MT(S) 9006) at 10:00am, or per institutional routine, on days-7 and -6 after fludarabine. Cyclophosphamide 60mg/kg/day intravenous (IV) x 2 days, total dose 120 mg/kg (days -7 and -6) Dosing is calculated based on Actual BodyWeight (ABW) unless ABW \> 30 kg above Ideal BodyWeight (IBW), in which case the dose should be computed using adjusted body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Patients will receive cyclosporine (CSA) therapy beginning on day -3 maintaining a level of \> 200 ng/mL. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Fludarabine 25 mg/m2/day intravenously (IV) x 3 days, total dose 75 mg/m2 (days -8 to -6);

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: All patients will begin mycophenolate mofetil (MMF) on day -3. Patients ≥ 40 kilograms will receive MMF at the dose of 3 grams/day divided into 2 or 3 doses (every 12 or 8 hours).~Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg three times a day.
Study: NCT01400243

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Placebo patch
Study: NCT00309842

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: The product is infused via intravenous (IV) drip directly into the central line without a needle, pump or filter.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: The recommended TBI is 165 cGy given twice daily for a total dose of 1320 cGy (days -4 to -1).
Study: NCT00561080

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zostavax

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zostavax

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zostavax
Study: NCT03946904

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG Laser
Description: Patients with towo similar size lesions of either Class I or class v cavities selected as subjects. in the same appointment, both cavities are prepared by the Er'Cr:YSGG. one lesion was prepared with high power laser setting first to ablate the enamel, dentin, and caries. the other lesion was prepared with low power setting to start and is aimed at applying low level laser therapy (LLLT) first before using high power.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG Laser
Description: Patients with towo similar size lesions of either Class I or class v cavities selected as subjects. in the same appointment, both cavities are prepared by the Er'Cr:YSGG. one lesion was prepared with high power laser setting first to ablate the enamel, dentin, and caries. the other lesion was prepared with low power setting to start and is aimed at applying low level laser therapy (LLLT) first before using high power.
Study: NCT04460547

Intervention type: DRUG
Intervention: Convalescent Plasma Transfusion
Description: Convalescent Plasma Transfusion to COVID-19 infected patients.

Intervention type: DRUG
Intervention: Convalescent Plasma Transfusion
Description: Convalescent Plasma Transfusion to COVID-19 infected patients.

Intervention type: DRUG
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine administration to COVID-19 infected patients.

Intervention type: DRUG
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine administration to COVID-19 infected patients.

Intervention type: DRUG
Intervention: DAS181
Description: DAS181 administration to COVID-19 infected patients.

Intervention type: DRUG
Intervention: DAS181
Description: DAS181 administration to COVID-19 infected patients.

Intervention type: DRUG
Intervention: Ivermectin
Description: Ivermectin administration to COVID-19 infected patients.

Intervention type: DRUG
Intervention: Ivermectin
Description: Ivermectin administration to COVID-19 infected patients.

Intervention type: DRUG
Intervention: Interferon Beta-1A
Description: Interferon Beta-1A administration to COVID-19 infected patients.

Intervention type: DRUG
Intervention: Interferon Beta-1A
Description: Interferon Beta-1A administration to COVID-19 infected patients.
Study: NCT01736150

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Starting dose of 1 tablet (800mg), three times per day (2.4g/day)with meals.~* If serum phosphorus is higher than 5.5 mg/dL on Visit 3, 4, or 5, then dose increased by one additional tablet (800 mg). Three times daily with meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate
Description: * Starting dose 1 tablet (800 mg), three times per day (2.4 g/day) with meals.~* If serum phosphorus is higher than 5.5 mg/dL on Visit 3, 4, or 5, then dose increased by one additional tablet(800mg).Three times daily with meals.
Study: NCT03330522

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Love, Sex, & Choices video series
Description: Love, Sex, and Choices was written and scripted by the study team and underwent pilot testing in the target population. The series was divided into 15-to-20 minute episodes that were streamed weekly. The principles of reducing HIV risk were communicated through the characters and high risk situations. The lead characters model how women become more powerful, meaning more aware of themselves as worthy of respect, making choices intentionally, feeling free to pursue their intentions, and involving themselves in creating change. This process leads to higher power sex scripts in the characters, meaning pursuing intentional choices and health promoting behaviors. The lead characters model open communication about HIV testing with a resistant partner, and initiating condom use.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Messages in text
Description: The comparison group received 12 weekly HIV health promotion written messages over the smartphone. The messages were based on prevailing CDC recommendations and the theoretical framework. An example is: Sexual health means respecting your own rights and feelings. Feeling pressured to have sex means limiting your choices and your freedom to love safely. .... If he doesn't like you being you, it may be time to walk. Other messages provided instructions on the correct condom use and the importance of HIV testing. The 12 messages were reviewed by ten African American and Latina undergraduate nursing students for ease of comprehension.
Study: NCT03204305

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 11C-OMAR
Description: 11C-OMAR is a PET radiotracer that binds to cannabinoid type 1 receptors (CB1R). It is an analog of the CB1R antagonist/inverse agonist rimonabant. 11C-OMAR was developed, synthesized and validated for inhuman use at the Johns Hopkins University PET center.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 11C-OMAR
Description: 11C-OMAR is a PET radiotracer that binds to cannabinoid type 1 receptors (CB1R). It is an analog of the CB1R antagonist/inverse agonist rimonabant. 11C-OMAR was developed, synthesized and validated for inhuman use at the Johns Hopkins University PET center.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis
Description: Cannabis will be administered to cannabis users. Doses include 0 and 25 mg THC.
Study: NCT00954902

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Antioxidant Spice Blend
Description: 14.5 g spice blend incorporated into a delivery meal including: cloves, cinnamon, oregano, rosemary, ginger, black pepper, paprika, garlic powder, and turmeric.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Antioxidant Spice Blend
Description: 14.5 g spice blend incorporated into a delivery meal including: cloves, cinnamon, oregano, rosemary, ginger, black pepper, paprika, garlic powder, and turmeric.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Trier Psychological Stressor
Description: This is a psychological stressor that is used to invoked stress responses in human subjects. Subjects are told they are taped and evaluated and deliver the speech in front of a trained panel of judges.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trier Psychological Stressor
Description: This is a psychological stressor that is used to invoked stress responses in human subjects. Subjects are told they are taped and evaluated and deliver the speech in front of a trained panel of judges.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo antioxidant concentrate
Description: Placebo capsules

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo antioxidant concentrate
Description: Placebo capsules
Study: NCT00455429

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules to JNJ-26113100 (50 milligram \[mg\]) orally once daily or 100 mg orally once daily or 100 mg orally twice daily or 250 mg orally twice daily for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-26113100 (50 mg) once daily
Description: JNJ-26113100 (50 mg) capsules orally once daily for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-26113100 (100 mg) once daily
Description: JNJ-26113100 (100 mg) capsules orally once daily for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-26113100 (100 mg) twice daily
Description: JNJ-26113100 (100 mg) capsules orally twice daily for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-26113100 (250 mg) twice daily
Description: JNJ-26113100 (250 mg) capsules orally twice daily for 6 weeks.
Study: NCT04183920

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry juice
Description: cranberry juice cocktail provided by Ocean Spray Cranberries, Inc.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry juice
Description: cranberry juice cocktail provided by Ocean Spray Cranberries, Inc.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo juice
Description: apple juice added with flavor and colorants provided by Ocean Spray Cranberries, Inc.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo juice
Description: apple juice added with flavor and colorants provided by Ocean Spray Cranberries, Inc.